Modality
Multispecific
MOA
PD-L1i
Target
CD38
Pathway
Checkpoint
IPF
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
~Apr 2021
→ ~Jul 2022
Phase 2
~Oct 2022
→ ~Jan 2024
Phase 3
~Apr 2024
→ ~Jul 2025
NDA/BLA
Oct 2025
→ Jan 2028
NDA/BLACurrent
NCT05592737
2,889 pts·IPF
2025-10→2028-01·Recruiting
2,889 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-251.8y awayPh3 Readout· IPF
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2028-01-25 · 1.8y away
IPF
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05592737 | NDA/BLA | IPF | Recruiting | 2889 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN |